drug

recombinant human tissue kallikrein

1 story · latest Aug 10, 2026

Status: Investigational
Code: DM199
Trials: 1 registered trial in coverage

Relationships

Developed by DiaMedica Therapeutics Inc

Timeline

DiaMedica reports Q2 2026 results, adds FGR enrollment and PE dose plans

Aug 10Quarterly updateDiaMedica Therapeutics Inc

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.